Gainers
- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares climbed 31.8 percent to $40.7376 as the company reported topline Phase 2 results from an ongoing trial of etrasimod called OASIS after Monday's market close.
- MuleSoft, Inc. (NASDAQ:MULE) gained 22 percent to $40.28 after the company was named as a potential acquisition target. Mulesoft, a provider of integration software for connecting applications, data and devices, is in advanced talks to be acquired by salesforce.com, inc. (NYSE:CRM), Reuters reported.
- Stoneridge, Inc. (NYSE:SRI) gained 16.3 percent to $28.81.
- MediWound Ltd. (NASDAQ:MDWD) shares rose 16 percent to $5.45.
- CASI Pharmaceuticals, Inc. (NASDAQ:CASI) gained 15.3 percent to $3.70.
- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) shares climbed 14.5 percent to $4.6849.
- PAR Technology Corporation (NYSE:PAR) gained 14.5 percent to $13.51.
- ACM Research, Inc. (NASDAQ:ACMR) rose 14.2 percent to $13.05.
- Vivint Solar, Inc. (NYSE:VSLR) gained 13.4 percent to $3.80. Vivint Solar disclosed that it won four awards at the 12th annual Stevie® Awards for Sales & Customer Service.
- ReTo Eco-Solutions, Inc. (NASDAQ:RETO) rose 12.3 percent to $9.53.
- Restoration Robotics, Inc. (NASDAQ:HAIR) gained 11.63 percent to $7.87 after the company disclosed that it has received the FDA clearance for implantation function.
- HealthEquity, Inc. (NYSE:HQY) gained 11.1 percent to $64.35 following Q4 results.
- Dolphin Entertainment, Inc. (NASDAQ:DLPN) shares climbed 10.8 percent to $3.38.
- BlackBerry Limited (NYSE:BB) rose 4 percent to $13.2101 following the announcement of a partnership with Microsoft Corporation (NASDAQ:MSFT) for "Blackberry Enterprise BRIDGE," to allow Microsoft apps, office programs within BlackBerry dynamics.
Check out these big penny stock gainers and losers
Losers
- Proteostasis Therapeutics, Inc. (NASDAQ:PTI) shares fell 19.3 percent to $5.640 in pre-market trading after reporting proposed public offering of common stock.
- OncoCyte Corporation (NYSE:OCX) dropped 18.6 percent to $1.75.
- Northern Oil and Gas, Inc (NYSE:NOG) dropped 15.6 percent to $1.92 after the company announced a $105 million offering. The company also raised FY18 production growth guidance.
- Westmoreland Resource Partners, LP (NYSE:WMLP) shares dropped 15 percent to $2.0062. Westmoreland is expected to release quarterly results on April 2.
- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shares fell 14.6 percent to $10.71.
- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) shares declined 13.3 percent to $22.83.
- Arcadia Biosciences, Inc. (NASDAQ:RKDA) shares dropped 12.7 percent to $39.8467.
- LexinFintech Holdings Ltd. (NASDAQ:LX) shares fell 11.1 percent to $16.22 following Q4 results.
- CHF Solutions, Inc. (NASDAQ:CHFS) declined 11.1 percent to $3.55 following Q4 results.
- Presbia PLC (NASDAQ:LENS) dropped 11 percent to $3.07.
- Alio Gold Inc. (NYSE:ALO) fell 9.9 percent to $1.950.
- Oracle Corporation (NYSE:ORCL) fell 9.3 percent to $47.11 despite reporting a third quarter earnings beat. Adjusted earnings came in at 83 cents per share, beating estimates by 11 cents. Sales came in at $9.776 billion, versus estimates of $9.781 billion.
- Duluth Holdings Inc. (NASDAQ:DLTH) shares dropped 8 percent to $17.34 following Q4 results.
- The Children's Place, Inc. (NASDAQ:PLCE) fell 7.1 percent to $129.10. Children's Place reported upbeat earnings for its fourth quarter, while sales misses estimates. The company also announced a $250 million buyback plan.
BBBlackBerry Ltd
$4.400.21%
CASICASI Pharmaceuticals Inc
$0.968410.1%
CRMSalesforce Inc
$255.000.04%
DLPNDolphin Entertainment Inc
$1.555.44%
DLTHDuluth Holdings Inc
$2.20-0.46%
HQYHealthEquity Inc
$96.00-%
LENSSarmaya Thematic ETF
$38.13-0.82%
LXLexinFintech Holdings Ltd
$3.150.64%
MDWDMediWound Ltd
$18.77-%
MSFTMicrosoft Corp
$474.54-0.39%
NOGNorthern Oil & Gas Inc
$21.790.46%
ORCLOracle Corp
$187.88-0.41%
PARPAR Technology Corp
$36.371.99%
PLCEChildren's Place Inc
$4.99-32.1%
RETOReTo Eco-Solutions Inc
$2.03-2.40%
RKDAArcadia Biosciences Inc
$3.57-1.92%
SRIStoneridge Inc
$6.00-%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
